Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent for trial P06029 as well as for the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the pharmacogenetic analysis (if applicable).~* Female and \>=35 to \<=42 years of age with indication for COS and IVF/ICSI.~* Body weight ≥50.0 kg, body mass index (BMI) \>=18.0 to \<=32.0 kg/m2.~* Regular spontaneous menstrual cycle with variation not outside the 24-35 days.~* Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed).~* Results of clinical laboratory tests, cervical smear, physical examination within normal limits or clinically acceptable to the investigator.~* Adhere to trial schedule.~Exclusion Criteria:~* A recent history of/or any current endocrine abnormality.~* A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS).~* A history of/or current polycystic ovary syndrome.~* More than 20 basal antral follicles \<11 mm (both ovaries combined) in the early follicular phase.~* Less than 2 ovaries or any other ovarian abnormality.~* Unilateral or bilateral hydrosalpinx.~* Intrauterine fibroids ≥5 cm or any clinically relevant pathology, which could impair embryo implantation or pregnancy continuation.~* More than three unsuccessful COS cycles for IVF/ICSI since the last established ongoing pregnancy (if applicable).~* A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG) treatment.~* A history of recurrent miscarriage.~* FSH \>15.0 IU/L or luteinizing hormone (LH) \>12.0 IU/L during the early follicular phase.~* Positive for human immunodeficiency virus (HIV) or Hepatitis B.~* Contraindications for the use of gonadotropins or gonadotropin releasing hormone (GnRH) antagonists.~* A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment.~* Smoking or recently stopped smoking (ie, within the last 3 months prior to signing informed consent).~* A recent history or presence of alcohol or drug abuse.~* The participant or the sperm donor has known gene defects, genetic abnormalities, or abnormal karyotyping, relevant for the current indication or for the health of the offspring.~* Prior or concomitant medications disallowed by protocol.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Single injection of 150 µg SCH 900962 (MK-8962) (Type: EXPERIMENTAL): Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
- Daily 300 IU recFSH (Type: ACTIVE_COMPARATOR): Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete